In vitro study | CYT387 effectively and selectively acts on JAK1 and JAK2 with IC50 of 11 nM and 18 nM, respectively, which is 9 times more effective than the closely related JAK3 kinase (IC50 of 155 nM). In Vitro, CYT387 inhibits the proliferation of IL-3 stimulated parental Ba/F3 cells (Ba/F3-wt) with an IC50 of 1400 nM. Moreover, CYT387 acts on cell lines that constitutively activate JAK2 or MPL signaling, including Ba/F3-MPLW515L cells, CHRF-288-11 cells, and Ba/F3-TEL-JAK2 cells, and also inhibits cell proliferation, IC50 was 200 nM, 1 nM and 700 nM respectively. In addition, CYT387 had a similar effect in inhibiting erythroid colony growth of jak2v617f-positive PV patients in vitro, with an IC50 of 2 μ-4 μm. Recent studies have shown that CYT387 inhibits IL-6-and IGF-1-induced PI3K/AKT and Ras/MAPK signaling. Moreover, CYT387 alone and in combination with traditional anti-MM therapeutic drugs Bortezomib and Melphalan act on primary multiple myeloma (MM) cells to induce apoptosis. |